Should I buy or sell Stereotaxis stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stereotaxis in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" STXS shares. View STXS analyst ratings or view top-rated stocks .

What is Stereotaxis' stock price target for 2024?

2 brokers have issued 1 year price targets for Stereotaxis' stock. Their STXS share price targets range from $4.00 to $5.00. On average, they predict the company's share price to reach $4.50 in the next year. This suggests a possible upside of 83.7% from the stock's current price. View analysts price targets for STXS or view top-rated stocks among Wall Street analysts .

How have STXS shares performed in 2024?

Stereotaxis' stock was trading at $2.87 at the beginning of the year. Since then, STXS stock has decreased by 14.6% and is now trading at $2.45. View the best growth stocks for 2024 here .

How were Stereotaxis' earnings last quarter?

Stereotaxis, Inc. (NYSEAMERICAN:STXS) released its quarterly earnings data on Monday, March, 4th. The company reported ($0.07) EPS for the quarter, hitting the consensus estimate of ($0.07). The firm earned $4.57 million during the quarter, compared to the consensus estimate of $7.55 million. Stereotaxis had a negative trailing twelve-month return on equity of 103.37% and a negative net margin of 77.37%.

What guidance has Stereotaxis issued on next quarter's earnings?

Stereotaxis issued an update on its first quarter 2024 earnings guidance on Monday, March, 4th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $7.0 million-$7.0 million, compared to the consensus revenue estimate of $6.7 million.

Who are Stereotaxis' major shareholders?

Stereotaxis' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include GSG Advisors LLC (0.03%). View institutional ownership trends .

How do I buy shares of Stereotaxis?

Shares of STXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NYSEAMERICAN:STXS

Stereotaxis (STXS) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free STXS Stock Alerts

$2.45

-0.13 (-5.04%)

(As of 04/18/2024 ET)

Compare

Today's Range: $2.45
▼
$2.60
50-Day Range: N/A
52-Week Range: $1.33
▼
$3.29

Volume: 237,388 shs
Average Volume: 385,965 shs
Market Capitalization: $201.22 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.50

Stock Analysis Analyst Forecasts Chart Earnings Headlines Insider Trades Ownership Short Interest

Get Stereotaxis alerts:

Stereotaxis MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 83.7% Upside
$4.50 Price Target
Short Interest: Healthy
1.34% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.23) to ($0.16) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.59 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Stereotaxis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Stereotaxis has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
1.34% of the float of Stereotaxis has been sold short.
Short Interest Ratio / Days to Cover
Stereotaxis has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Stereotaxis has recently increased by 5.57%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Stereotaxis does not currently pay a dividend.
Dividend Growth
Stereotaxis does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for STXS.

0.6

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Stereotaxis this week, compared to 1 article on an average week.
Search Interest
Only 2 people have searched for STXS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
5 people have added Stereotaxis to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Stereotaxis insiders have not sold or bought any company stock.
Percentage Held by Insiders
18.52% of the stock of Stereotaxis is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
45.35% of the stock of Stereotaxis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Stereotaxis are expected to grow in the coming year, from ($0.23) to ($0.16) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Stereotaxis is -8.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Stereotaxis is -8.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Stereotaxis has a P/B Ratio of 12.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad TradeSmith

The A.I. story nobody is telling you (Read ASAP)

There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...

Click here to see Louis' new video for yourself.

About Stereotaxis Stock (NYSEAMERICAN:STXS)

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane, full-power x-ray system, including c-arm, powered table, motorized boom, and monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. It markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with MAGiC catheter for cardiac ablation procedures. Stereotaxis, Inc. was incorporated in 1990 and is based in Saint Louis, Missouri.

STXS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

STXS Stock News Headlines

April 19, 2024 | investorplace.com

3 Penny Stocks That Could Make a Big Comeback by the End of Q2

April 17, 2024 | barrons.com

Stereotaxis Inc.

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 10, 2024 | investorplace.com

7 Penny Stocks That Could 5X by the End of 2024

March 19, 2024 | markets.businessinsider.com

Stereotaxis Set for Breakout Growth: Buy Rating Affirmed Amidst Regulatory Advances and Robust Financials

March 17, 2024 | investorplace.com

Low-Priced, High-Potential: 7 Cheap Stocks Under $10 to Try Your Luck With

March 9, 2024 | seekingalpha.com

Major Regulatory Approvals Coming For Stereotaxis In The Next 10 Months

March 6, 2024 | seekingalpha.com

Stereotaxis, Inc. (STXS) Q4 2023 Earnings Call Transcript

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 6, 2024 | bizjournals.com

St. Louis public company projects 'breakout growth' as revenue falls, loss widens

March 5, 2024 | finance.yahoo.com

Stereotaxis, Inc. (AMEX:STXS) Q4 2023 Earnings Call Transcript

March 4, 2024 | benzinga.com

Recap: Stereotaxis Q4 Earnings

March 4, 2024 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Stereotaxis (STXS), LifeMD (LFMD)

March 4, 2024 | globenewswire.com

Stereotaxis Announces Regulatory Submissions of the MAGiC Ablation Catheter in Europe and the United States

March 4, 2024 | globenewswire.com

Stereotaxis Reports 2023 Full Year Financial Results

March 3, 2024 | msn.com

Stereotaxis Q4 2023 Earnings Preview

March 1, 2024 | benzinga.com

Earnings Preview For Stereotaxis

February 23, 2024 | markets.businessinsider.com

Lake Street Keeps Their Buy Rating on Stereotaxis (STXS)

February 23, 2024 | finanznachrichten.de

Stereotaxis, Inc.: Intermountain Health Extends Leadership in Heart Care with Adoption of Advanced Robotic Technology

February 22, 2024 | finance.yahoo.com

Intermountain Health Extends Leadership in Heart Care with Adoption of Advanced Robotic Technology

February 22, 2024 | globenewswire.com

Intermountain Health Extends Leadership in Heart Care with Adoption of Advanced Robotic Technology

February 20, 2024 | finance.yahoo.com

Stereotaxis to Report Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024

February 20, 2024 | globenewswire.com

Stereotaxis to Report Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024

February 18, 2024 | morningstar.com

Stereotaxis Inc STXS

January 11, 2024 | nasdaq.com

Roth MKM Initiates Coverage of Stereotaxis (STXS) with Buy Recommendation

January 8, 2024 | finanznachrichten.de

Stereotaxis, Inc.: Stereotaxis Announces First Patients Successfully Treated Using MAGiC Ablation Catheter

January 8, 2024 | finance.yahoo.com

Stereotaxis Announces First Patients Successfully Treated Using MAGiC Ablation Catheter

See More Headlines

Receive STXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Stereotaxis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/04/2024
Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSEAMERICAN
Sector: Medical
Industry: Electromedical equipment
Sub-Industry: N/A
Current Symbol: NYSEAMERICAN:STXS
CUSIP: N/A
CIK: N/A
Web: www.stereotaxis.com
Phone: (314) 678-6100
Fax: 314-678-6159
Employees: 122
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $4.50
High Stock Price Target: $5.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +83.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.28)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-20,710,000.00
Net Margins: -77.37%
Pretax Margin: -77.37%
Return on Equity: -103.37%
Return on Assets: -44.67%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.51
Quick Ratio: 1.88

Sales & Book Value

Annual Sales: $26.77 million
Price / Sales: 7.52
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.20 per share
Price / Book: 12.25

Miscellaneous

Outstanding Shares: 82,130,000
Free Float: 66,919,000
Market Cap: $201.22 million
Optionable: Not Optionable
Beta: 1.34

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

Dr. David Leo Fischel C.A.I.A. (Age 37)
C.F.A., C.P.A., M.B.A., CEO & Chairman
Comp: $62.2k
Ms. Kimberly R. Peery (Age 55)
CFO & Secretary
Comp: $251.84k
Mr. Keith Galloway
Vice President of Operations
Ms. Laura Spencer Garth
General Counsel & Secretary
Mr. Guy Judkowski
Equity Portfolio Manager

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

STXS Stock Analysis - Frequently Asked Questions

Should I buy or sell Stereotaxis stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stereotaxis in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" STXS shares.
View STXS analyst ratings or view top-rated stocks.
What is Stereotaxis' stock price target for 2024?: 2 brokers have issued 1 year price targets for Stereotaxis' stock. Their STXS share price targets range from $4.00 to $5.00. On average, they predict the company's share price to reach $4.50 in the next year. This suggests a possible upside of 83.7% from the stock's current price.
View analysts price targets for STXS or view top-rated stocks among Wall Street analysts.
How have STXS shares performed in 2024?: Stereotaxis' stock was trading at $2.87 at the beginning of the year. Since then, STXS stock has decreased by 14.6% and is now trading at $2.45.
View the best growth stocks for 2024 here.
How were Stereotaxis' earnings last quarter?: Stereotaxis, Inc. (NYSEAMERICAN:STXS) released its quarterly earnings data on Monday, March, 4th. The company reported ($0.07) EPS for the quarter, hitting the consensus estimate of ($0.07). The firm earned $4.57 million during the quarter, compared to the consensus estimate of $7.55 million. Stereotaxis had a negative trailing twelve-month return on equity of 103.37% and a negative net margin of 77.37%.

What guidance has Stereotaxis issued on next quarter's earnings?: Stereotaxis issued an update on its first quarter 2024 earnings guidance on Monday, March, 4th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $7.0 million-$7.0 million, compared to the consensus revenue estimate of $6.7 million.
Who are Stereotaxis' major shareholders?: Stereotaxis' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include GSG Advisors LLC (0.03%).
View institutional ownership trends.
How do I buy shares of Stereotaxis?: Shares of STXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSEAMERICAN:STXS) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial